Condition: Triple Negative Breast Cancer · Residual Disease · Sponsor: Dartmouth-Hitchcock Medical Center
There are two parts to this study. It is a phase 1b followed by a randomized phase 2 study to assess whether adding 3 years of adjuvant tetrathiomolybdate (TM) to standard 6 months treatment of adjuvant capecitabine and pembrolizumab in high risk for relapse triple negative breast cancer. In the phase 1b part of the study, TM is added to adjuvant capecitabine and pembrolizumab in high risk for relapse triple negative breast cancer (RCB 2, 3, risk for relapse \>60% at 5 years) after completion of neoadjuvant chemo-immunotherapy and surgery to establish the safety of the combination. This will be followed by a randomized phase 2 clinical trial of adjuvant TM and capecitabine vs capecitabine alone. If pembrolizumab was administered in the neoadjuvant setting, it may be continued in the adjuvant setting per investigator discretion.
This description comes directly from the study's public registry record.
Raven J Lavoie, RN · (603) 653-3661 · Raven.M.Lavoie@hitchcock.org
Naomi Kornhauser, MPH · naomi.t.kornhauser@hitchcock.org
Always discuss trial participation with your own doctor first.
| Indiana University Simon Cancer Center | Indianapolis, Indiana, United States | Not Yet Recruiting |
| Dartmouth Hitchcock Medical Center | Lebanon, New Hampshire, United States | Recruiting |
| NYU Langone perimutter Cancer Center | New York, New York, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06134375